Development of a rapid neutralization testing system for Rhinovirus C15 based on the enzyme-linked immunospot assay.
Rhinovirus C15
enzyme-linked immunospot assay
neutralization assay
neutralizing antibody
seroprevalence
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
07
2022
accepted:
25
08
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
11
10
2022
Statut:
epublish
Résumé
Human Rhinoviruses (RVs) are dominant pathogens causing a wide range of respiratory tract diseases, posing a huge threat to public health worldwide. Viruses belonging to the RV-C species are more likely to cause severe illnesses and are strongly associated with asthma onset or exacerbations than RV-A or RV-B. Rapid and sensitive detection of neutralizing antibodies (NAbs) against RV-C can promote the development of vaccines and antiviral drugs and help in the diagnosis of viral infection. In this study, a rapid neutralization testing system for RV-C15, based on an enzyme-linked immunospot assay (Nt-ELISPOT) was developed. A monoclonal antibody (MAb), named 9F9, with high binding efficacy for RV-C15 conjugated to horseradish peroxidase (HRP), was used to detect RV-C15-infected cells at a concentration of 2 μg/ml. The optimal infectious dose of RV-C15 was set at 1 × 10
Identifiants
pubmed: 36212859
doi: 10.3389/fmicb.2022.983656
pmc: PMC9539532
doi:
Types de publication
Journal Article
Langues
eng
Pagination
983656Informations de copyright
Copyright © 2022 Zhou, Zhu, Yang, Xu, Chen, Wu, Yin, Huang, Zhang, Liu, Que, Zhang, Xia and Cheng.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Virol Methods. 2021 Jan;287:113995
pubmed: 33068703
Diagn Microbiol Infect Dis. 2022 Jun;103(2):115676
pubmed: 35405611
ACS Infect Dis. 2020 May 8;6(5):811-819
pubmed: 31840495
PLoS One. 2011;6(5):e20005
pubmed: 21603631
Emerg Infect Dis. 2004 Jun;10(6):1095-101
pubmed: 15207063
Nat Rev Immunol. 2018 May;18(5):297-308
pubmed: 29379211
Am J Respir Crit Care Med. 2021 Apr 1;203(7):822-830
pubmed: 33357024
Appl Microbiol Biotechnol. 2019 Feb;103(4):1931-1938
pubmed: 30617817
Curr Allergy Asthma Rep. 2016 Apr;16(4):30
pubmed: 26960297
Clin Vaccine Immunol. 2014 Mar;21(3):312-20
pubmed: 24391137
Eur Respir J. 2011 May;37(5):1037-42
pubmed: 20693244
BMJ Open. 2017 Apr 3;7(4):e013034
pubmed: 28373249
Nat Med. 2011 May;17(5):627-32
pubmed: 21483405
J Microbiol Immunol Infect. 2020 Aug;53(4):561-568
pubmed: 30591259
Pediatr Infect Dis J. 2019 Mar;38(3):e59-e62
pubmed: 30001231
Viruses. 2021 Feb 25;13(3):
pubmed: 33668934
Rev Med Virol. 2021 Jul;31(4):e2193
pubmed: 33217098
Annu Rev Med. 2019 Jan 27;70:91-104
pubmed: 30691364
J Infect Dis. 2020 Jun 29;222(2):324-332
pubmed: 32108877
Expert Rev Respir Med. 2020 Aug;14(8):777-789
pubmed: 32498634
Viruses. 2022 Jan 13;14(1):
pubmed: 35062345
Emerg Microbes Infect. 2018 Jan 10;7(1):2
pubmed: 29323107
Pediatr Allergy Immunol. 2006 Nov;17(7):514-8
pubmed: 17014626
Clin Infect Dis. 2000 Mar;30(3):611-2
pubmed: 10722460
Nat Commun. 2017 Sep 11;8(1):505
pubmed: 28894095
J Med Virol. 2006 Sep;78(9):1232-40
pubmed: 16847968
Clin Microbiol Rev. 2013 Jan;26(1):135-62
pubmed: 23297263
Eur J Pediatr. 2014 Jul;173(7):913-9
pubmed: 24493557
Virol J. 2016 Mar 18;13:44
pubmed: 26987753